1.https://enterabio.com/news.

2.Effects of TST002(Blosozumab) in Chinese subjects with reduced bone mineral density: a single ascending dose trial. 2024 WCO-IOF-ESCEO abstract P557.

3.Recker RR, Benson CT, Matsumoto T, Bolognese MA, Robins DA, Alam J, Chiang AY, Hu L, Krege JH, Sowa H, Mitlak BH, Myers SL. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015;30(2):216-24.

4.McClung MR, Brown JP, Diez-Perez A, Resch H, Caminis J, Meisner P, Bolognese MA, Goemaere S, Bone HG, Zanchetta JR, Maddox J, Bray S, Grauer A. Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study. J Bone Miner Res. 2018;33(8):1397-1406.

5.Ling Qin, Wingyee Choy, Szeki Au, Musei Fan, Pingchung Leung. Alendronate increases BMD at appendicular and axial skeletons in patients with established osteoporosis. J Orthop Surg Res . 2007:2:9.

6.Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-65.

7.1994 FDA GUIDELINES FOR PRECLINICAL AND CLINICAL EVALUATION OF AGENTS USED IN THE PREVENTION OR TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS.

8.Vilaca T, Schini M, Lui LY, Ewing SK, Thompson AR, Vittinghoff E, Bauer DC, Eastell R, Black DM, Bouxsein ML.The relationship between treatment-related changes in total hip BMD measured after 12, 18, and 24 mo and fracture risk reduction in osteoporosis clinical trials: the FNIH-ASBMR-SABRE project. J Bone Miner Res . 2024 Sep 26;39(10):1434-1442.

9.https://ir.transcenta.com/media/auygnfwr/2021091400016_c.pdf

10.https://www.sbichinacapital.com/research/pdf/6628.pdf